AI Can Diagnose You with This Progressive Illness — and It's 86% Accurate, Study Says
A tool accessible via smart home devices can help diagnose people with Parkinson's disease.
The AI-powered tool was developed as part of a study by scientists at University of Rochester.
The tool prompts users to perform neurological tests in their own homes that involve speech, facial expression and finger movementsA tool accessible via smart home devices can help diagnose people with Parkinson's disease.
The AI-powered tool, called PARK, was developed as part of a study by scientists at University of Rochester.
According to the website, the tool prompts users to perform a variety of web-based neurological tests in their own homes that involve speech, facial expression and finger movements.
The tasks are then analyzed to detect whether the user shows signs of Parkinson's disease. After the results are given, the tool provides personalized resources for treatment or care.
Newsweek reports that the test asks users to recite two short sentences that use every letter of the alphabet at least once. Then, in mere seconds, the AI can analyze the recordings to look for patterns linked to the disease.
The toll has an 86% accuracy rate, per Newsweek.
PARK can be accessed by any major web browser, but the researchers also note that it can be a useful tool for smart home devices, such as Amazon Alexa or Google Assistant.
Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human-interest stories.
"While we haven't established partnerships with these companies yet, our model is very lightweight and well-suited for such integration," computer scientist Tariq Adnan told Newsweek.
"With appropriate privacy safeguards and user consent, it could operate passively or on-demand through such widely used home devices,' he added. 'Once integrated, [in theory] a user could say something like 'screen me for Parkinson's symptoms,' and the system would prompt a short sentence to be read aloud.'
The tool was trained with data from over 1,300 participants in home care settings, clinical settings and at the InMotion Parkinson's disease care center in Ohio, according to Newsweek. Possible indicators for the disease include uttering sounds, pausing, breathing and adding "features of unintelligibility," according to computer science graduate student Abdelrahman Abdelkader.
The researchers note that access to neurological care can be a barrier for people to receive clinical diagnoses, and believe the tool can be used to encourage people to seek medical evaluation if they suspect they have the disease.
"We envision a gentle, user-centered experience. The tool would never deliver a diagnosis, rather would only flag whether a follow-up with a clinician might be worthwhile," Adnan said.
Parkinson's disease is characterized by the loss of nerve cells in the brain, per Mayo Clinic. It is unknown what causes the disease, although genes and environmental factors may play a risk.
The average onset of Parkinson's disease is around 70 years old.
Symptoms of the disease include memory loss, trouble with language, feeling irritable, having trouble chewing and swallowing, and difficulty sleeping.
Parkinson's Foundation states that about 1.1 million people in the United States have the disease.
Read the original article on People
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
30 minutes ago
- Business Wire
Lysoway Therapeutics Awarded Grant from The Michael J. Fox Foundation to Advance TRPML1 Agonist to Treat Parkinson's Disease
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Lysoway Therapeutics, Inc., a biopharmaceutical company developing small molecule modulators of lysosomal ion channels, today announced that it has received a research grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF). Support comes from MJFF's Parkinson's Disease Therapeutics Pipeline Program, which focuses on candidates with strong potential to slow or halt disease progression or alleviate burdensome symptoms for those living with Parkinson's disease. Lysoway Therapeutics funding of $2.93 million will support the preclinical and translational development of Lysoway's novel, highly brain-penetrant small molecule TRPML1 agonist. This funding will allow us to accelerate the preclinical development of our lead TRPML1 agonist, with the goal of initiating first-in-human clinical trials early in year 2026 Share The study aims to investigate whether activating TRPML1 by a novel, small molecule modulator, will enhance the lysosomal membrane calcium ion channel to restore lysosomal function and help with clearance of alpha-synuclein, the protein that is linked to the disease. 'We are honored to receive this generous grant from The Michael J. Fox Foundation,' said Valerie Cullen, PhD, Principal Investigator and SVP of Research and Translation at Lysoway. 'TRPML1 is a high value target due to its pivotal role in sensing and responding to cellular stress. By activating this ion channel, we can engage multiple beneficial pathways that restore autophagy/lysosomal homeostasis and bolster cellular resilience. Our lead development candidate is both orally bioavailable and highly brain-penetrant, offering strong potential to modify disease progression in Parkinson's Disease.' Yongchang Qiu, PhD, Founder and Chief Executive Officer of Lysoway Therapeutics, added 'This funding underscores growing confidence in TRPML1 as a compelling target for Parkinson's disease. It will allow us to accelerate development of our lead TRPML1 agonist and to establish key biomarkers for target engagement, with the goal of initiating first-in-human clinical trials early next year.'
Newsweek
31 minutes ago
- Newsweek
Potato Salad Recall Map Shows New Warning Issued in 5 States
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Hans Kissle is recalling its Red Potato Bliss Salad due to an undeclared wheat allergen discovered in a labeling error. Newsweek reached out to the company for comment via phone on Tuesday night and left a voicemail. Why It Matters Numerous recalls have been initiated this year due to the potential of damaged products, foodborne illness, contamination and undeclared food allergens. Millions of Americans experience food sensitivities or allergies every year. According to the U.S. Food and Drug Administration (FDA), the nine "major" food allergens in the U.S. are eggs, milk, fish, wheat, soybeans, Crustacean shellfish, sesame, tree nuts and peanuts. People with a wheat allergy could experience a "serious or life-threatening allergic reaction if they consume these products," the FDA warns. What To Know In the alert, the FDA says that 66 units of the potato salad are being recalled because of the mislabeling issue. The product is packaged in a 16-ounce container that is clear and has a white lid. The product's UPC Code number is 036217673706 and has a use-by date of August 20, 2025. The container says, "Hans Kissle Tri Color Twist Pasta Salad" while the top says, "Hans Kissle Red Bliss Potato Salad," the FDA says. There have been no reported illnesses or adverse reactions as it relates to this recall as of Tuesday, the FDA says. The recalled potato salads were distributed to Stop & Shop retail locations in five states, the alert notes. Below is a map showing the affected states, which include New York, New Jersey, Rhode Island, Connecticut and Massachusetts. What People Are Saying The FDA in the alert, in part: "The recall was initiated after it was discovered that 66 containers of Tricolor Twist Pasta Salad were mislabeled with the incorrect top label. While the front label correctly identifies the product, the top label misrepresents it as Red Bliss Potato Salad. The actual product contains wheat, which is not declared on the top label." In an email to Newsweek in January, the FDA said: "Most recalls in the U.S. are carried out voluntarily by the product manufacturer and when a company issues a public warning, typically via news release, to inform the public of a voluntary product recall, the FDA shares that release on our website as a public service. The FDA's role during a voluntary, firm-initiated, recall is to review the recall strategy, evaluate the health hazard presented by the product, monitor the recall, and as appropriate alert the public and other companies in the supply chain about the recall." It added: "The FDA provides public access to information on recalls by posting a listing of recalls according to their classification in the FDA Enforcement Report, including the specific action taken by the recalling company. The FDA Enforcement Report is designed to provide a public listing of products in the marketplace that are being recalled." Additional information on recalls can be found via the FDA's Recalls, Market Withdrawals, & Safety Alerts. What Happens Next Consumers are advised to return the recalled product to the original place of purchase for a full refund, the FDA says. People with additional questions may contact the company via phone at 978-556-4500 from 8 a.m. to 5 p.m. ET weekdays.
Newsweek
2 hours ago
- Newsweek
Women's Global Impact 2025: Day of Networking, Panels Inspires Attendees
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Some of the most powerful and well-connected women in business gathered at Newsweek's New York headquarters at One World Trade Center today for the company's inaugural Women's Global Impact Forum. The event kicked off with a breakfast and continued with opening remarks by Newsweek's Editor-in-Chief Jennifer Cunningham who set the stage for the topics of the day, including entrepreneurship, gender equity, women's health, transformations in customer engagement, directing business from the board room, leadership, artificial intelligence, female audiences and how to define having it all. Across 12 panel discussions and three fireside chats, over 300 guests listened to high-profile guests from Mercedes-Benz, the American Heart Association, SoulCycle, Sakara, Clinique, Hulken and Nissan dispense invaluable advice and tell stories of their success. One attendee said, "Everything feels really actionable and relatable" when describing the morning's panel lineup. In addition to the discussions, attendees were able to mingle with one another and learn about each other's respective industries and the impact they were making through their work. "What I observe in our wellness industry are so many fads, whether it's pursuing cold plunges, protein, Pilates," SoulCycle CEO Evelyn Webster told the crowd. She added that the biggest killer of women in America was heart disease and that exercise was an essential part of staying healthy and well. "That doesn't mean you need to be running marathons. It means that you need balance, a balanced exercise regimen," she said. "So if that is with SoulCycle, great! But even if it's not SoulCycle, please move your body and get your heart pumping 150 minutes a week." Webster added that exercise also helped to shape better business leaders. Quoting Legally Blonde icon Elle Woods, she said, "Exercise gives you endorphins, endorphins make you happy. And happy people just make better leaders." The crowd ate it up. Many attendees showed interest as Kelly Fanning, general manager of Clinique and Dermatological Brands, North America, shared the unusual "reverse mentorship" program offered by her parent company, Estée Lauder. "Estée Lauder has a long-standing, very formalized program of reverse mentoring," Fanning explained. "Essentially, what it is is more junior-level talent in our organization has the opportunity to be connected with VP-level and above, and they mentor us. NFL VP Sarah Bishop chats with Women's Global Impact attendees during a networking session on Tuesday, August 5, 2025. NFL VP Sarah Bishop chats with Women's Global Impact attendees during a networking session on Tuesday, August 5, 2025. Weston Kloefkorn | For Newsweek "The first time I did it, I had no idea how to prepare, because I think through our career as a mentor, when you have a mentee, you think about questions you're going to ask," she continued, adding that she'd had a meeting with her reverse mentor on Tuesday morning. "And from the past year, I've learned TikTok differently. I've gone to a store to shop Sephora with them, see how they shop. What do they do? Why don't they pick our brands? Why do they pick our brands? I've learned AI and how to do the most easy tasks, all the way through to 'Hey, how do I take all this data and just make a report to pull that off my team's plate?' Right?" During the lunch break, attendees dined on a variety of fare with a New York City theme. After, the panel discussions continued. Daniella Pierson, founder and CEO of The Newsette and CHASM, discussed how to achieve gender equality in the workplace. "I believe the way that we are actually going to have gender equality... is by making as many badass female entrepreneurs as we can," she said. KaLeigh Long, founder & CEO of Westwin Elements, urged her fellow female Gen Z aspiring business leaders to focus on "doing something, not being someone." The day concluded with a one-on-one interview of Indra Nooyi, former chairman and CEO of PepsiCo, by Cunningham, and a cocktail reception. Glasses at the Women's Global Impact Forum cocktail hour sponsored by Hers at One World Trade Center in New York City. Glasses at the Women's Global Impact Forum cocktail hour sponsored by Hers at One World Trade Center in New York City. Weston Kloefkorn | For Newsweek "Speaking at Newsweek's Women's Global Impact Forum was more than an honor—it was a powerful reminder of what's possible when purpose-driven leadership meets collective ambition. At Nissan, we know that real change begins with listening, learning and leading boldly. Being surrounded by trailblazing women from across industries reaffirmed the strength of our voices and the impact of our actions. Thank you to Newsweek for championing progress and creating space for meaningful dialogue," Allyson Witherspoon, chief marketing officer of Nissan U.S., told Newsweek.
